CagriSema: Cagrilintide + Semaglutide Trial Results, Status and Limits

CagriSema is Novo Nordisk’s investigational once-weekly fixed-dose combination of cagrilintide 2.4 mg (long-acting amylin analog) and semaglutide 2.4 mg (GLP-1 receptor agonist). It sits in the obesity-pipeline conversation next to dual agonists and triple agonists — but it is not “stronger Wegovy,” and it is not an approved consumer product as of this review.

Short answer: Late-stage trials show large average weight loss for CagriSema versus placebo and versus some active comparators, with a December 2025 U.S. NDA submission for weight management. That is a regulatory milestone, not FDA approval. Gray-market “cagrilintide + sema” stacks are not CagriSema.

Related reading:

• Amylin component: cagrilintide
• Semaglutide class: semaglutide as GLP-1
• Approved dual agonist: semaglutide vs tirzepatide
• Triple agonist pipeline: retatrutide · tirzepatide vs retatrutide
• Category map: peptides for weight loss
• Hormone primer: what is GLP-1

Educational only — not medical advice. Investigational products belong in trial and regulatory context. Do not treat trial milligram schedules as a personal protocol.

Status box

Question	Current framing
What is it?	Fixed combination: cagrilintide 2.4 mg + semaglutide 2.4 mg, once weekly SC in trials
Developer	Novo Nordisk
Main programs	REDEFINE (obesity / overweight); REIMAGINE (type 2 diabetes)
U.S. regulatory	NDA submitted December 2025 for weight management (REDEFINE 1 & 2 package); not approved
Practical access today	No labeled CagriSema pharmacy product; approved alternatives exist for eligible patients
Research-market risk	Loose cagrilintide vials ≠ clinical CagriSema

Mechanism: two pathways, one weekly injection (in trials)

Component	Pathway	Why it is in the combination
Semaglutide 2.4 mg	GLP-1 receptor agonist	Appetite, gastric emptying, glycemic effects already established in Wegovy/Ozempic-class products
Cagrilintide 2.4 mg	Long-acting amylin analog	Satiety and post-meal metabolic signaling via amylin pathways — not a GLP-1

Design hypothesis: amylin + GLP-1 together may improve weight outcomes versus semaglutide alone. That is a clinical question answered by combination trials, not by buying two research powders and stacking them.

CagriSema is not:

• A dual GIP/GLP-1 agonist (that is tirzepatide’s design)
• A triple GIP/GLP-1/glucagon agonist (that is retatrutide’s design)
• Proof that “any amylin peptide online” is the same molecule

Evidence map (what to cite)

Program / layer	What it answers	How to read it
Phase 2 cagrilintide monotherapy	Does amylin analog alone move weight?	Dose-finding; not CagriSema itself
Early combination / Phase 2 combo work	Safety and signal for co-administration	Smaller / earlier than REDEFINE
REDEFINE 1	Obesity/overweight without diabetes; vs placebo and active arms including semaglutide alone	Core weight-management package trial (~68 weeks; large N)
REDEFINE 2	Type 2 diabetes + overweight/obesity vs placebo	Metabolic comorbidity population
REDEFINE 4	Head-to-head style comparison vs tirzepatide	Open-label Phase 3 toplines; estimands matter; noninferiority not met per company communications
REIMAGINE program	Type 2 diabetes development path	Separate from pure weight-management labeling questions

REDEFINE 1 figures (peer-reviewed / ADA symposium framing)

REDEFINE 1 (phase 3; adults with obesity or overweight + comorbidity, without type 2 diabetes; ~68 weeks) is the core weight-management package trial. Public ADA / NEJM-linked reporting for mean body-weight change includes:

Analysis framing	CagriSema	Semaglutide 2.4 mg	Cagrilintide 2.4 mg	Placebo
Treatment-policy / regardless-of-adherence style	−20.4%	−14.9%	−11.5%	−3.0%
Trial-product / if-all-adhered style	−22.7%	−16.1%	−11.8%	−2.3%

Estimand choice moves the headline by a few points. Prefer the PubMed/NEJM record over social recaps when citing. Primary record: PubMed 40544433.

REDEFINE 4 vs tirzepatide (important reality check)

Company toplines for open-label REDEFINE 4 reported substantial weight loss for CagriSema (about 23% on an efficacy / all-adhered style figure at 84 weeks) but did not meet noninferiority versus tirzepatide 15 mg on the primary comparison (tirzepatide figures higher on the same topline estimands in public summaries).

That does not make CagriSema “useless.” It means the marketing story “beats everything” failed a specific noninferiority test against the leading dual agonist. For patients today, approved tirzepatide remains the practical dual-agonist option when clinically appropriate.

Cross-pipeline comparison (not a ranking badge)

Option	Design	Access framing	Rough public weight signal
Semaglutide (Wegovy)	GLP-1	Approved when labeled/prescribed	~15% class pivot (STEP 1-style)
Tirzepatide (Zepbound)	GIP + GLP-1	Approved when labeled/prescribed	Up to ~21% SURMOUNT-1 high dose; beat CagriSema on REDEFINE 4 noninferiority
CagriSema	Amylin + GLP-1 fixed combo	Investigational (NDA filed)	~20–23% REDEFINE 1-style; large but not noninferior to tirzepatide in REDEFINE 4 toplines
Retatrutide	GIP + GLP-1 + glucagon	Investigational	Very high Phase 2/3 topline averages; different program

Cross-trial % columns mislead without duration, population, diabetes mix and estimand. Use them as orientation, not a scoreboard.

Safety and tolerability

Expect a GI-dominant adverse-event story:

• Nausea, vomiting, diarrhea, constipation
• Appetite reduction that can overshoot intake
• Escalation-related flares familiar from GLP-1 starts

Because CagriSema contains semaglutide, class-relevant label themes from Wegovy/Ozempic-type products still matter in discussion (pancreatitis signals, gallbladder disease with rapid weight loss, dehydration/kidney stress, retinopathy caution in some diabetes contexts, thyroid C-cell / MTC–MEN2 contraindication language on GLP-1 labels). Cagrilintide adds its own investigational safety dataset; it does not have years of post-marketing pharmacovigilance as a solo approved drug.

Deep class page: GLP-1 side effects.

Dosing culture: trial schedules are not consumer labels

Trials used once-weekly subcutaneous combination product concepts with titration. Public shorthand often quotes 2.4 mg / 2.4 mg maintenance targets for the combination.

That is not:

• Permission to combine research cagrilintide with compounded semaglutide
• A conversion chart from Wegovy pens
• Proof that a gray-market multi-vial stack matches clinical CagriSema

If a product is eventually approved, the USPI and clinician judgment will own dosing — not blogs.

Choose X if / choose Y if

Situation	Practical lean	Why
Needs an approved obesity medicine now	Semaglutide / tirzepatide / other labeled options when eligible	CagriSema is not approved
Tracking Novo’s next combination product	Follow CagriSema REDEFINE / FDA timeline	Amylin + GLP-1 is a real pipeline lane
Comparing to Lilly dual/triple agonists	Read REDEFINE 4 + tirzepatide/retatrutide pages	Different mechanisms and access
Considering research “cagrilintide + sema” vials	Do not equate with CagriSema	Identity, purity, dose and combo PK are not guaranteed

Who this page is for / not for

For: readers tracking obesity pipeline combinations, comparing amylin + GLP-1 to dual/triple agonists, and separating NDA headlines from pharmacy access.

Not for: DIY research stacks, “switch from Zepbound to CagriSema” internet protocols, or assuming REDEFINE averages will appear on an unregulated vial.

Diabetes and comorbidity programs

REDEFINE 2 embeds type 2 diabetes + overweight/obesity. Separate REIMAGINE readouts explore CagriSema in diabetes development paths. Glycemic and weight endpoints can both move; that does not make the combination a substitute for labeled diabetes care today. Approved agents still own routine prescribing.

Blood-pressure and cardiometabolic secondary analyses appear in the broader publication trail as data mature — cite the primary papers, not influencer recaps.

Myths

Myth	Better framing
NDA filed = approved and available	Filing starts review; label and supply come later if approved
CagriSema is just high-dose Wegovy	Fixed combo with amylin analog + semaglutide
It beat tirzepatide	REDEFINE 4 toplines: large loss, noninferiority not met
Two research vials = CagriSema	Clinical product is a defined combination under trial controls

What this page is not

• A buying guide for unapproved combination vials
• A claim that CagriSema “beats tirzepatide” after REDEFINE 4
• Medical advice or a titration protocol

Bottom line

CagriSema is a serious, late-stage amylin + GLP-1 combination with large trial weight-loss averages and a U.S. NDA filing in late 2025. It is still investigational. For care today, approved medicines win on access and labeling. For literacy, track estimands, head-to-head toplines and the difference between clinical CagriSema and research-market lookalikes.

Next: cagrilintide for the amylin component alone · semaglutide vs tirzepatide for approved options · retatrutide results for the other pipeline headline.

References

1. Garvey WT, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1). PubMed 40544433.

2. Davies MJ, et al. Cagrilintide–semaglutide in adults with overweight or obesity and type 2 diabetes (REDEFINE 2). PubMed 40544432.

3. American Diabetes Association newsroom. CagriSema REDEFINE 1 / 2 symposium summary (20.4% / 22.7% framing; REDEFINE 2 ~13.7%). June 2025.

4. Frias JP, et al. Co-administered cagrilintide 2.4 mg with semaglutide 2.4 mg in type 2 diabetes.

5. Lau DCW, et al. Once-weekly cagrilintide phase 2 dose-finding for weight management.

6. Novo Nordisk via PR Newswire. U.S. NDA filing for CagriSema weight management (18 Dec 2025).

7. Company topline coverage of REDEFINE 4. Open-label vs tirzepatide; noninferiority not met — treat as topline until full peer-reviewed paper is primary.

8. DailyMed. Wegovy (semaglutide) prescribing information — class warnings relevant because CagriSema contains semaglutide.